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Abstract
Background: Circular RNAs are a subgroup of non-coding RNAs and generated by a mammalian genome. Herein,
the expression and function of circular RNA circ-TTBK2 were investigated in human glioma cells.
Methods: Fluorescence in situ hybridization and quantitative real-time PCR were conducted to profile the cell distribution
and expression of circ-TTBK2 and microRNA-217 (miR-217) in glioma tissues and cells. Immunohistochemical and western
blot were used to determine the expression of HNF1β and Derlin-1 in glioma tissues and cells. Stable knockdown of
circ-TTBK2 or overexpression of miR-217 glioma cell lines (U87 and U251) were established to explore the function of
circ-TTBK2 and miR-217 in glioma cells. Further, luciferase reports and RNA immunoprecipitation were used to investigate
the correlation between circ-TTBK2 and miR-217. Cell Counting Kit-8, transwell assays, and flow cytometry were used to
investigate circ-TTBK2 and miR-217 function including cell proliferation, migration and invasion, and apoptosis, respectively.
ChIP assays were used to ascertain the correlations between HNF1β and Derlin-1.
Results: We found that circ-TTBK2 was upregulated in glioma tissues and cell lines, while linear TTBK2 was not dysregulated
in glioma tissues and cells. Enhanced expression of circ-TTBK2 promoted cell proliferation, migration, and invasion, while
inhibited apoptosis. MiR-217 was downregulated in glioma tissues and cell lines. We also found that circ-TTBK2, but not
linear TTBK2, acted as miR-217 sponge in a sequence-specific manner. In addition, upregulated circ-TTBK2 decreased
miR-217 expression and there was a reciprocal negative feedback between them in an Argonaute2-dependent manner.
Moreover, reintroduction of miR-217 significantly reversed circ-TTBK2-mediated promotion of glioma progression. HNF1β
was a direct target of miR-217, and played oncogenic role in glioma cells. Remarkably, circ-TTBK2 knockdown combined
with miR-217 overexpression led to tumor regression in vivo.
Conclusions: These results demonstrated a novel role circ-TTBK2 in the glioma progression.
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Background
Human malignant gliomas are the most common and
lethal primary brain tumor in adults [1, 2], and glioma
cells are featured as carrying heterogeneous genetic
molecular aberrations [3–5]. Despite the application
of advanced chemotherapy, radiotherapy, and surgery,
patients with this disease suffer a badly median
survival [6–8]. Hence, deeper elucidation of the
molecular mechanisms underlying glioma malignancy
may offer improved treatments of gliomas.
It has been confirmed that a large proportion (>90%)
of the human genome is actively transcribed, and most
of the transcripts are identified as non-coding RNAs
(ncRNAs) [9]. Circular RNAs (circRNAs), referred to as
ncRNAs, are different from the linear RNAs with a
circular structure by joining the 3′ end of the RNA to
the 5′ end [10, 11]. Recently, circRNAs have been found
to have multiple functions in various mammalian cells.
Most circRNAs are derived from exons, and most of
them are located in the cytoplasm [12]. Accumulated
evidence showed that circRNAs harbor microRNA
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(miRNA) binding sites and function as miRNA
sponges. For example, miR-138 targets the circular
RNA SRY in a sequence-specific manner [13]. In
addition, the circular RNA CiRS-7 possess a binding
site of miR-7 and modulate miR-7 expression [14].
Tau tubulin kinase 2 (TTBK2) was first identified as a
kinase which phosphorylated tau and tubulin [15].
Aberrant expression of linear TTBK2 is related to
various diseases. Overexpression of TTBK2 contrib-
utes to the progression of amyotrophic lateral sclerosis
[16]. More importantly, increased expression of
TTBK2 attenuates the sunitinib-induced apoptosis of
kidney carcinoma and melanoma cell lines [17].
Besides, our preliminary experiment demonstrated
that TTBK2 circular RNA (circ-TTBK2, also named
has_circ_0000594 according to circBase) was upregu-
lated in glioma tissues. Therefore, we hypothesized
that dysregulation of circ-TTBK2 was involved in the
regulation of glioma malignancy.
MiRNAs are characterized as a member of small non-
coding RNAs and have been confirmed to be involved in
both biological and pathological processes [18]. Expres-
sion profiling analysis has depicted a possible tumor-
suppressive function of miR-217 in various cancers. As
previously reported, miR-217 is robustly downregulated
in human epithelial ovarian cancer (EOC) and inhibits
cell growth and metastasis [19]. Additionally, miR-217
expression is downregulated and exerts a tumor-
suppressive function in gastric cancer [20]. Bioinformat-
ics software (Starbase) revealed that circ-TTBK2 harbor
a binding site of miR-217. However, the function of
miR-217 in glioma and circ-TTBK2/miR-217 functional
network in modulating glioma malignant behavior
remains unknown.
Hepatocyte nuclear factors (HNFs) were initially
identified as a group of transcription factors that were
involved in regulating the transcription of liver-
specific genes. Hepatocyte nuclear factor-1beta
(HNF1β) is the most important member of liver-
specific transcription factor and is responsible for
sequence-specific DNA binding. It is a homeobox
transcription factor functioning as a homodimer or
heterodimer with HNF1α [21]. In addition, HNF1β has
been characterized as an oncogene in various tumors.
HNF1β is upregulated in hepatocellular carcinoma
(HCC), and high level of HNF1β leads to poor overall
survival [22]. Also, HNF1β promotes malignant pro-
gression of ovarian clear cell carcinoma via facilitating
glucose uptake and glycolytic activity [23]. More im-
portantly, using bioinformatics softwares (Targetscan,
miRanda, and RNAhybrid), a binding site was identi-
fied between miR-217 and HNF1β. However, the po-
tential oncogenic function of HNF1β in glioma
remains poorly defined.
Derlin-1 participates in the dislocation of misfolded
proteins from endoplasmic reticulum (ER) and protects
cancer cells from endoplasmic reticulum stress-induced
apoptosis. Moreover, Derlin-1 expression is upregulated
in various tumors such as human breast carcinoma and
colon tumor [24, 25]. Besides, previous reports unveiled
that overexpressed Derlin-1 activated PI3K/AKT and
ERK signaling pathways [26, 27]. Also, by scanning the
promoter sequence of Derlin-1, we found a putative
binding site of HNF1β. Although the oncogenic role of
Derlin-1 is confirmed in many tumors, whether Derlin-1
exerts oncogene function in glioma remains unclear.
In the present study, we investigated the expression
and functions of circ-TTBK2, miR-217, HNF1β, and
Derlin-1 in glioma tissues and cells. Circ-TTBK2, but
not linear TTBK2, exerted oncogenic role in glioma
cells. Furthermore, miR-217 targeted circ-TTBK2 in a
sequence-specific manner, miR-217 and circ-TTBK2
formed a negative feedback loop possibly mediated by
RNA-induced silencing complex (RISC). Moreover,
HNF1β was confirmed to harbor a binding site of miR-
217 using dual-luciferase assays. These results demon-
strated a detailed function of circ-TTBK2 in glioma and
provided a novel potential approach for glioma therapy.
Results
Circ-TTBK2, but not linear TTBK2, was upregulated in
glioma tissues and cell lines and played oncogenic
function in glioma cells
By scanning TTBK2 genome and circBase, we found that
circ-TTBK2 contained only exons and was generated
from exon 3, exon 4, exon 5, and exon 6 from TTBK2
gene (Fig. 1d). The expression of circ-TTBK2 in glioma
tissues and cells was determined by fluorescence in situ
hybridization (FISH) and quantitative real-time PCR
(qRT-PCR). Circ-TTBK2 was located in the cytoplasm
and was significantly upregulated in glioma tissues com-
pared with normal brain tissues (Fig. 1a). Circ-TTBK2
expression was significantly increased in glioma tissues
and cells (Fig. 1b, c). And the expression of circ-TTBK2
was positively correlated with the pathological grades of
glioma. However, linear TTBK2 expression was not
changed in glioma tissues and cells (Additional file 1:
Figure S1a, b). Furthermore, RNase R was used to con-
firm the circular form RNA was detected. As expected,
circ-TTBK2 was resistant to RNase R treatment, while
linear TTBK2 was significantly reduced in cells treated
with RNase R (Additional file 1: Figure S1c, d). These re-
sults showed that circ-TTBK2 dysregulation might con-
tribute to the malignant progression of glioma cells.
Stable circ-TTBK2 overexpression and inhibition in
glioma cells were established to investigate the role of
circ-TTBK2. To confirm the circular form of TTBK2
was force-expressed instead of the linear form, we
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Fig. 1 Circ-TTBK2 expression in glioma tissues and cell lines, enforced circ-TTBK2 promoted malignant progression of U87 and U251
glioma cells. a FISH was used to determine expression and location of circ-TTBK2 in glioma tissues and normal brain tissues (NBTs)
(green, circ-TTBK2; blue, DAPI nuclear staining). Scale bars represent 20 μm. b qRT-PCR was conducted to detect expression levels of
circ-TTBK2 in glioma tissues of different grades and NBTs (data are presented as the mean + SD (n = 11, NBTs group; n = 19, each
glioma tissue group). **P < 0.01 vs. NBTs group). c Expression levels of circ-TTBK2 in human normal astrocytes and glioma cell lines
(data are presented as the mean + SD (n = 5, each group). **P < 0.01 vs. normal human astrocyte group). d Cartoon of circ-TTBK2 arose
from TTBK2 gene. e CCK-8 assay was used to determine the proliferation effect of circ-TTBK2 on U87 and U251 cells. f Quantification
number of migration and invasion cells with overexpression or knockdown of circ-TTBK2. Representative images and accompanying
statistical plots were presented. g Flow cytometry analysis of U87 and U251 cells with the expression of circ-TTBK2 changed (data are
presented as the mean + SD (n = 5, each group). *P < 0.05 vs. circ-TTBK2 (+)-NC group; #P < 0.05 vs. circ-TTBK2 (−)-NC group. Scale bars
represent 40 μm)
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examined transfection efficiency and the TTBK2 expres-
sion after transfection of circ-TTBK2. As expected, circ-
TTBK2 expression was significantly higher in the circ-
TTBK2 (+) group, while its expression was significantly
lower in the circ-TTBK2 (−) group (Additional file 1:
Figure S1e). Also, no significant change of TTBK2 nei-
ther in the circ-TTBK2 (+) group nor circ-TTBK2 (−)
group (Additional file 2: Figure S2a). We also examined
circ-TTBK2 expression in cells treated with sh-TTBK2
(transfection efficiency of sh-TTBK2 data was shown in
Additional file 1: Figure S1f ). The results showed that
sh-TTBK2 did not influence circ-TTBK2 expression
(Additional file 2: Figure S2b). Inhibition of circ-TTBK2
led to a significant decrease in the proliferation com-
pared with the circ-TTBK2 (−)-NC group (Fig. 1e).
Transwell assay was used to measure whether circ-
TTBK2 dysregulation could affect the migration and in-
vasion of glioma cells. Cell number in the circ-TTBK2
(+) group was obviously increased compared with that
in the circ-TTBK2 (+)-NC group (Fig. 1f ). Moreover,
overexpressed circ-TTBK2 hindered apoptosis of glioma
cells compared with the circ-TTBK2 (+)-NC group
(Fig. 1g).
MiR-217 was downregulated in glioma tissues and cell
lines and exerted tumor-suppressive function in glioma
cells
MiR-217 expression levels in glioma tissues and cells
were analyzed by FISH and qRT-PCR. MiR-217
expression was negatively correlated with the patho-
logical grades of glioma, and similarly with circ-
TTBK2, miR-217 was also located in the cytoplasm
(Fig. 2a, b). Meanwhile, the expression of miR-217
was lower in U87 and U251 glioma cells than that in
normal human astrocytes (Fig. 2c). After transfection,
we first examined the transfection efficiency
(Additional file 1: Figure S1g). Restoration of miR-217
significantly inhibited glioma cell proliferation com-
pared with the pre-NC group (Fig. 2d). Also, overex-
pressed miR-217 decreased migrating and invading
cell numbers compared with that in the pre-NC group
(Fig. 2e). MiR-217 overexpression promoted apoptosis
of glioma cells compared with the pre-NC group
(Fig. 2f ). This inferred that miR-217 might function
as a tumor-suppressor in glioma cells.
MiR-217 functional targeted circ-TTBK2, but not TTBK2,
and reversed the circ-TTBK2-mediated promotion of gli-
oma cell progression
As previously mentioned, circRNAs could function as miR-
NAs sponge, and miRNAs could target circRNAs in a
sequence-specific manner. We assumed that circ-TTBK2
might harbor a binding site of miR-217 using bioinformat-
ics database (Starbase). To verify our prediction, dual-
luciferase gene reporter assay was conducted. The lucifer-
ase activity in the circ-TTBK2-Wt+miR-217 group was
significantly decreased than that in the circ-TTBK2-Wt
+miR-217-NC group (Fig. 3b), while the luciferase activity
in the circ-TTBK2-Mut+miR-217 group was not changed.
Two putative binding sites were identified in linear TTBK2.
However, the luciferase assays TTBK2-Wt+miR-217 did
not influence the luciferase activity, while TTBK2-Wt1
+miR-217 decreased the luciferase activity (Additional file
2: Figure S2e, f). Further, we measured miR-217 expression
in the circ-TTBK2 (+) and circ-TTBK2 (−) groups by qRT-
PCR. MiR-217 expression was significantly decreased in the
circ-TTBK2 (+) group, while miR-217 expression was sig-
nificantly increased in the circ-TTBK2 (-) group (Fig. 3c).
Similarly, the expression of circ-TTBK2 was significantly re-
stored in anti-miR-217 group (Fig. 3d). Also, we found that
overexpression or downregulation of miR-217 did not affect
the expression of TTBK2 (Additional file 2: Figure S2c).
RNA-binding protein immunoprecipitation (RIP) assay
was conducted to investigate whether circ-TTBK2 and
miR-217 were involved in the expected RNA-induced si-
lencing complex (RISC) complex. RNA levels in immu-
noprecipitates were detected by qRT-PCR. The relative
enrichment levels of circ-TTBK2 and miR-217 were both
increased in the anti-Ago2 group than those in the anti-
normal group. In the anti-miR-217 group, the relative
enrichment levels of circ-TTBK2 and miR-217 immuno-
precipitated with Ago2 were lower than those in the
control group, respectively (Fig. 3e–h). In summary,
these results indicated that circ-TTBK2 reduced miR-
217 expression in RISC manner, and there might be a re-
ciprocal repression feedback loop between circ-TTBK2
and miR-217.
Having confirmed that miR-217 expression was nega-
tively regulated by circ-TTBK2 expression, we further
investigated whether miR-217 reversed circ-TTBK2-
mediated promotion of glioma cells progression. The
proliferation of glioma cells in the circ-TTBK2 (+)+miR-
217 (−) group was significantly increased than that in
the circ-TTBK2 (+)+miR-217 (+) group (Fig. 3i). Further,
circ-TTBK2 introduction combined with miR-217 inhib-
ition led to an increased cell number compared with
circ-TTBK2 (+)+miR-217 (+) (Fig. 3j). Moreover, glioma
cells treated with circ-TTBK2 (−)+miR-217 (+) exhibited
higher ratio of apoptosis compared with cells treated
with circ-TTBK2 (−)+miR-217 (−) (Fig. 3k). These re-
sults clarified that circ-TTBK2 promoted glioma cells
malignant progression via reducing miR-217 expression.
HNF1β was a target of miR-217, and was involved in circ-
TTBK2- and miR-217-mediated modulation of glioma cells
malignant progression
Using bioinformatics databases (TargetScan, miRanda,
and RNAhybrid), HNF1β was identified as a direct target
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Fig. 2 miR-217 expression in glioma tissues and cell lines: restoration of miR-217 restrained the malignant progression of glioma cells. a FISH was
used to determine expression and location of miR-217 in glioma tissues and normal brain tissues (NBTs) (red, miR-217; blue, DAPI nuclear staining).
Scale bars represent 20 μm. b qRT-PCR was conducted to detect expression levels of miR-217 in glioma tissues of different grades and NBTs (data
are presented as the mean + SD (n = 11, NBTs group; n = 19, each glioma tissue group). **P < 0.01 vs. NBT group). c Expression levels of miR-217 in
human normal astrocytes and glioma cell lines (data are presented as the mean + SD (n = 5, each group). **P < 0.01 vs. normal human astrocyte
group). d CCK-8 assay was applied to evaluate the proliferation effect of miR-217 on U87 and U251 cells. e Quantification number of migration
and invasion cells with different expression levels of miR-217. Representative images and accompanying statistical plots were presented. Scale
bars represent 40 μm. f Flow cytometry analysis of U87 and U251 cells with the expression of miR-217 changed (data are presented as the mean
+ SD (n = 5, each group). *P < 0.05 vs. pre-NC group; #P < 0.05 vs. anti-NC group)
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of miR-217. The luciferase activity in the HNF1β-Wt
+miR-217 group was significantly attenuated than that
in the HNF1β-Wt+miR-217-NC group, while the lucifer-
ase activity in the HNF1β-Mut+miR-217 group was not
affected (Fig. 4b). Accumulated evidence showed that
HNF1β was upregulated in various tumors and exerted
key roles in molecular events in cells. HNF1β was lo-
cated to the nucleus and was positively correlated with
the progression of glioma pathological grades (Fig. 4c).
Furthermore, protein levels of HNF1β were significantly
higher in low- and high-grade glioma tissues than those
in normal brain tissues (Fig. 4d). In addition, HNF1β
protein levels were upregulated in U87 and U251 cells
compared with normal human astrocytes. Moreover,
qRT-PCR and western blot were used to determine the
expressions of HNF1β mRNA and protein in glioma
cells treated with circ-TTBK2 inhibition and/or miR-217
overexpression. mRNA and protein expressions of
HNF1β were robustly reduced than that in the circ-
TTBK2 (−)-NC group (Fig. 4e). While mRNA and pro-
tein expressions of HNF1β were significantly decreased
in the pre-miR-217 group compared with those in the
pre-NC group (Fig. 4f ). Moreover, mRNA and protein
expressions of HNF1β were obviously upregulated in the
circ-TTBK2 (+)+miR-217 (−) group than those in the
circ-TTBK2 (+)+miR-217 (+) group (Fig. 4g).
HNF1β promoted malignant progression of glioma cells
and bound to the promoter of Derlin-1
Having confirmed that HNF1β was upregulated in gli-
oma tissues and cells, effects of HNF1β overexpression
or downregulation on glioma cells were investigated.
The transfection efficiency of HNF1β was confirmed
(Additional fie 3: Figure S1h). Cell proliferation in the
HNF1β (+) group was significantly upregulated versus
that in HNF1β (+)-NC group (Fig. 5a). Moreover, trans-
well assays showed that the migrating and invading cell
numbers in the HNF1β (−) group were reduced com-
pared with those in the HNF1β (-)-NC group (Fig. 5b).
Flow cytometry analysis was used to measure whether
HNF1β affected the apoptosis of glioma cells. Cells
treated with HNF1β (+) exhibited lower apoptosis ratio
than that in the HNF1β (+)-NC group (Fig. 5c).
HNF1β specifically binds to the “GTTAAT box” which
is presented in promoters of target genes [28]. Accord-
ing to DBTSS HOME database, promoter sequence of
Derlin-1 was set. By scanning the DNA sequence in the
2000 bp region upstream and 200 bp region downstream
of the transcription start site (TSS), two putative HNF1β
binding sites were identified. Chromatin immunoprecipi-
tation (ChIP) assays were performed to determine
whether HNF1β was directly associated with Derlin-1
promoters in U87 and U251 cells. As a negative control,
1000 bp upstream region of the putative HNF1β binding
site was amplied using PCR, which was not expected to
associate with HNF1β. There was a direct association of
HNF1β with putative binding site 2 of Derlin-1 (Fig. 5d).
And there were no interactions of HNF1β with the con-
trol region or putative binding site 1.
Further, Derlin-1 protein expression was detected in
U87 and U251 cells treated with HNF1β (+) or HNF1β
(-). Overexpressed HNF1β significantly increased Derlin-
1 protein expression than that in the HNF1β (+)-NC
group (Fig. 5e). These results demonstrated that HNF1β
acted as an oncogene in glioma cells and could upregu-
late Derlin-1 expression by directly activating promoter
of Derlin-1.
Derlin-1 promoted cell proliferation, migration, and
invasion, while inhibited apoptosis of glioma cells
Since Derlin-1 could be upregulated by HNF1β, we first
examined the expression and function of Derlin-1 in gli-
oma tissues and cells. Immunohistochemistry (IHC) re-
sults showed that Derlin-1 protein was located in
cytoplasm and was positively correlated with the pro-
gression of glioma pathological grades (Fig. 6a). More-
over, Derlin-1 expression levels were obviously higher in
low- and high-grade glioma tissues than in normal brain
(See figure on previous page.)
Fig. 3 Overexpression of circ-TTBK2 promoted malignant biological behavior of glioma cells via decreasing miR-217 expression. a The predicted
miR-217 binding site in circ-TTBK2 (circ-TTBK2-Wt) or and the designed mutant sequence (circ-TTBK2-Mut) were indicated. b Luciferase reporter
assay of HEK 293T cells co-transfected with circ-TTBK2-Wt or circ-TTBK2-Mut and miR-217 or the miR-217-NC (data are presented as the mean +
SD (n = 5, each group). *P < 0.05 vs. circ-TTBK2-Wt+miR-217-NC group). c qRT-PCR analysis for circ-TTBK2 regulated miR-217 expression in U87 and
U251 cells (data are presented as the mean + SD (n = 5, each group). **P < 0.01 vs. circ-TTBK2 (+) group; ##P < 0.01 vs. circ-TTBK2 (−)-NC group). d
qRT-PCR analysis for miR-217 attenuated circ-TTBK2 expression in U87 and U251 cells (data are presented as the mean + SD (n= 5, each group). **P< 0.01
vs. pre-NC group; ##P< 0.01 vs. anti-NC group). e–hmiR-217 was identified in circ-TTBK2-RISC complex. Relative enrichment of circ-TTBK2 and miR-217 were
measured using qRT-PCR (data represent mean + SD (n= 5, each group). *P< 0.05, **P< 0.01 vs. anti-normal IgG respective group, #P< 0.05, ##P< 0.01 vs.
anti-Ago2 in control group). i CCK-8 assay was applied to evaluate the proliferation effect of circ-TTBK2 and miR-217 on U87 and U251 cells (data are
presented as the mean + SD (n = 5, each group). *P < 0.05 vs. circ-TTBK2 (+)+miR-217 (+) group; #P < 0.05 vs. circ-TTBK2 (−)+miR-217(−) group; ▲P <
0.05 vs. control group). j Quantification number of migration and invasion cells with the expression of circ-TTBK2 and miR-217 changed. Representative
images and accompanying statistical plots were presented (data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. circ-TTBK2 (+)+miR-
217 (+) group; #P < 0.05 vs. circ-TTBK2 (−)+miR-217(−) group; ▲P < 0.05 vs. control group. Scale bars represent 40 μm). k Flow cytometry analysis of
U87 and U251 with the expression of circ-TTBK2 and miR-217 changed (data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. circ-
TTBK2 (+)+miR-217 (+) group; #P < 0.05 vs. circ-TTBK2 (−)+miR-217(−) group; ▲P < 0.05 vs. control group)
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tissues. Similarly, Derlin-1 had a higher expression levels
in U87 and U251 cells than those in human normal as-
trocytes (Fig. 6b). Further, effects of Derlin-1 on glioma
cell biological behavior were determined. The transfec-
tion efficiency of Derlin-1 was determined by western
blot (Additional file 1: Figure S1i). Overexpression of
Derlin-1 led to an increased cell proliferation than that
in the Derlin-1 (+)-NC group (Fig. 6c). Migrating and in-
vading cells in the Derlin-1 (+) group were obviously in-
creased compared with the Derlin-1 (+)-NC group
(Fig. 6d). The apoptosis of cells treated with Derlin-1 (+)
was impaired versus Derlin-1 (+)-NC group (Fig. 6e).
These results showed that Derlin-1 functioned as an
oncogene in glioma cells.
Overexpressed miR-217 impaired HNF1β-induced promo-
tion of glioma cell progression and regulated signaling
pathways by targeting 3′-UTR of HNF1β
The above results showed that circ-TTBK2 modulated
HNF1β expression via regulating miR-217 expression,
and HNF1β increased Derlin-1 expression by activating
the promoter of Derlin-1. To clarify whether HNF1β re-
versed miR-217-induced impairment of malignant pro-
gression of glioma cells, we measured the biological
behavior of glioma cells that stably expressed miR-217
+HNF1β (non-3′UTR). Proliferation of glioma cells in
the miR-217+HNF1β (non-3′UTR) group was signifi-
cantly restored than that in the miR-217+HNF1β group
(Fig. 7a). Furthermore, numbers of migrating and invad-
ing cells in the miR-217+HNF1β (non-3′UTR) group
were increased versus those in the miR-217+HNF1β
group (Fig. 7b). Moreover, glioma cells treated with miR-
217+HNF1β (non-3′UTR) showed a lower apoptosis ra-
tio than cells treated with miR-217+HNF1β (Fig. 7c).
As previously reported, Derlin-1 exerted oncogenic
function by activating PI3K/AKT and ERK pathways; we
next examined the expression of proteins involved in
these signaling pathways. Derlin-1, p-PI3K, p-AKT,
p-ERK, and p-MEK1/2 expression levels were signifi-
cantly restored in the miR-217+HNF1β (non-3′UTR)
group than those in the miR-217+HNF1β group
(Fig. 7d).
Knockdown of circ-TTBK2 combined with overexpression
of miR-217 inhibited tumor growth and led to higher
survival in nude mice
The in vivo experiment showed downregulated circ-
TTBK2 or overexpressed miR-217 (Fig. 8b). Remarkably,
knockdown of circ-TTBK2 combined with miR-217
overexpression resulted in the smallest tumor volume
(Fig. 8b). The survival analysis demonstrated that in
circ-TTBK2 inhibition, miR-217 reintroduction led to
longer survival than the control group. And circ-TTBK2
inhibition combined with miR-217 overexpression pro-
duced the longest survival period (Fig. 8b).
Discussion
In this study, we demonstrated that circ-TTBK2 was up-
regulated in glioma tissues and cell lines. Overexpression
of circ-TTBK2 promoted glioma cells malignant pro-
gression. In contrary, miR-217 was downregulated in gli-
oma tissues and cell lines. Restoration of miR-217
restrained glioma cells malignant progression. Moreover,
miR-217 bound to circ-TTBK2 in a sequence-dependent
manner and there was a reciprocal negative feedback
between circ-TTBK2 and miR-217. Further, overexpres-
sion of circ-TTBK2 increased HNF1β expression via
impairing miR-217 expression which negatively regu-
lated HNF1β by targeting its 3′-UTR. HNF1β was up-
regulated in glioma tissues and cells and promoted cell
proliferation, migration, and invasion, while inhibited
apoptosis of glioma cells. Meanwhile, HNF1β enhanced
(See figure on previous page.)
Fig. 4 HNF1β was upregulated in glioma tissues and cell lines and was a target of miR-217; both circ-TTBK2 and miR-217 could modulate HNF1β expression.
a The predicted miR-217 binding site in HNF1β (HNF1β-Wt) or and the designed mutant sequence (HNF1β-Mut) were indicated. b Luciferase reporter assay
of HEK 293T cells co-transfected with HNF1β-Wt or HNF1β-Mut and miR-217 or the miR-217-NC (data are presented as the mean + SD (n= 5, each group).
*P<0.05 vs. HNF1β-Wt+miR-217-NC group). c Immunohistochemistry of HNF1β protein in nontumorous brain, low-grade glioma, and high-grade glioma
tissues. Original magnification: 100×. Scale bar = 50 μm. d HNF1β protein expression levels in nontumorous brain tissues and glioma tissues using GAPDH as
an endogenous control. Representative protein expression and their integrated density values (IDVs) of HNF1β in nontumorous brain tissues, low-grade
glioma tissues (World Health Organization (WHO) I–II), and high-grade glioma tissues (WHO III-IV) are shown (data are presented as the mean+ SD (n= 15,
each group). **P < 0.01 vs. NBTs group; ##P < 0.01 vs. low-grade glioma tissues group). HNF1β protein expression levels in astrocytes, U87, and U251 cells and
using GAPDH as an endogenous control. Representative protein expression and their IDVs in human normal astrocytes, U87, and U251 are shown (data are
presented as the mean+ SD (n= 15, each group). **P < 0.01 vs. human normal astrocytes group). e qRT-PCR and western blot analysis for circ-TTBK2 regulated
HNF1β expression in U87 and U251 cells. The relative expression of HNF1βmRNA was shown using GAPDH as an endogenous control. The IDVs of PIWIL4
was shown using GAPDH as an endogenous control (data are presented as the mean + SD (n= 5, each group). *P < 0.05 vs. circ-TTBK2 (+)-NC group; #P <
0.05 vs. circ-TTBK2 (−)-NC group). f qRT-PCR and western blot analysis for miR-217 regulated HNF1β expression in U87 and U251. The relative expression of
HNF1βmRNA was shown using GAPDH as an endogenous control. The IDVs of HNF1β was shown using GAPDH as an endogenous control (data are
presented as the mean+ SD (n= 5, each group). *P < 0.05 vs. pre-NC group; #P < 0.05 vs. anti-NC group). g qRT-PCR and western blot analysis for circ-TTBK2
combined with miR-217 regulated HNF1β expression in U87 and U251. The relative expression of HNF1βmRNA was shown using GAPDH as an endogenous
control. The IDVs of HNF1β was shown using GAPDH as an endogenous control (data are presented as the mean + SD (n= 5, each group). *P < 0.05 vs.
circ-TTBK2 (+)+miR-217 (+) group; #P < 0.05 vs. circ-TTBK2 (−)+miR-217 (−) group)
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the promoter activity and bound to the promoter of
Derlin-1. In addition, Derlin-1, identified as an oncogene
in glioma tissues and cells, was involved in the HNF1β-
mediated promotion of glioma cells malignant progres-
sion. Overexpression of Derlin-1 facilitated malignancy
of glioma cells. Mechanistically, PI3K/AKT and ERK
pathways were involved in circ-TTBK2 regulated malig-
nant progression of glioma cells. Remarkably, the in vivo
study demonstrated that the inhibition of circ-TTBK2
and restoration of miR-217 exhibited the lowest tumor
volume and the longest survival tumor-bearing nude
mice.
Although circRNAs have been found decades ago,
their novel functions have remained unclear until re-
cently. Accumulated evidence indicated that dysregu-
lated expression of circRNAs were ubiquitously in
heterogeneous tumors and were involved in multiple
cellular biological processes in tumor cells [29, 30]. Not-
withstanding, mechanisms of circRNAs’ effect on tumor
cells are anfractuous and unclear. As earlier reported,
circ-Foxo3 expression was downregulated in several can-
cer cells than in non-cancer cells, and overexpressed
circ-Foxo3 inhibited cell proliferation through binding
to CDK2 and p21 [31]. Meanwhile, circ-Foxo3 expres-
sion level is upregulated in aged patient and mice
tissues, overexpression of circ-Foxo3 contributes to the
progression of senescence in mice Dox-induced cardio-
myopathy cells by interacting with ID1, E2F1, FAK, and
HIF1A [32]. Due to our preliminary result, circ-TTBK2
expression was upregulated in glioma tissues. Linear
TTBK2 was first characterized as a kinase in brain cells
that could phosphorylate Ser 208 and Ser 210 in tau
protein [33]. Also, mutated TTBK2 contributed to spi-
nocerebellar ataxia [34]. Remarkably, TTBK2 mRNA
expression was not changed in glioma tissues and cells.
Furthermore, neither circ-TTBK2 nor linear TTBK2
influenced respective expression level. Consistent with
several previous findings, we concluded circ-TTBK2 was
independent of linear TTBK2 [31, 35]. Moreover, en-
hanced circ-TTBK2 facilitated malignant progression of
glioma cells. Therefore, circ-TTBK2 might be involved
in the modulation of glioma cell biological behavior and
exerted critical function in glioma progression.
Accumulated evidence confirmed that circRNAs may
act as miRNAs sponges via binding to miRNAs and
modulate their function [36]. For example, circ_005169
exerted oncogenic function via sponging miR-145 and
increasing the expression of E2F5, BAG4, and FMNL2 in
colorectal cancer cells [37]. Bioinformatics database
(Starbase) showed that a putative binding site exists be-
tween circ-TTBK2 and miR-217. We further ascertained
that miR-217 targeted circ-TTBK2-Wt. This indicated
that circ-TTBK2 might sponge to miR-217 to modulate
its function in glioma cell. Interestingly, two putative
binding sites were identified in linear TTBK2. Our data
showed that miR-217 targeted TTBK2-Wt1, this binding
site was the same sequence as circ-TTBK2 harbored.
However, the binding site falls within the CDS region of
linear TTBK2 (not 3′ UTR). In addition, pre-miR-217
did not change the linear TTBK2 expression. This dem-
onstrated that the binding site between TTBK2 and
miR-217 was not functional. Further, we found that
there was a reciprocal negative feedback between circ-
TTBK2 and miR-217. The RIP assay results showed that
circ-TTBK2 and miR-217 were presented in the RISC
complex. This might partially explain why the expression
of circ-TTBK2 and miR-217 were negatively correlated.
We further investigated whether circ-TTBK2 exerted
oncogenic function in glioma through regulating miR-
217 and found that the restoration of miR-217 robustly
reversed the circ-TTBK2-induced promotion of glioma
cell malignant progression. These results demonstrated
that miR-217 could target circ-TTBK2 in a sequence-
specific manner, and there was a reciprocal repression
process between circ-TTBK2 and miR-217.
Notoriously, miR-217 was downregulated in various
tumors such as EOC and gastric cancer. Meanwhile,
overexpressed miR-217 obviously inhibited cell prolifera-
tion, colony formation, and invasion, while promoted
apoptosis of colorectal cancer cell via targeting AEG-1
3′-UTR [38]. Similarly, miR-217 was negatively corre-
lated with malignant profiling and exerted tumor-
suppressive function by restraining malignant biological
behavior of human osteosarcoma cells [39]. Further,
miR-217 expression was significantly lower in lung can-
cer tissues than in noncancerous tissues, and enhanced
(See figure on previous page.)
Fig. 5 HNF1β exerted oncogenic role and could modulate Derlin-1 expression via binding to its promoter region in glioma cells. a CCK-8 assay
was used to determine the proliferation effect of HNF1β on U87 and U251 cells. b Quantification number of migration and invasion cells with
overexpression or inhibition of HNF1β. Representative images and accompanying statistical plots were presented. Scale bars represent 40 μm. c
Flow cytometry analysis of U87 and U251 cells with the expression of HNF1β changed (data are presented as the mean + SD (n = 5, each group).
*P < 0.05 vs. HNF1β (+)-NC group; #P < 0.05 vs. HNF1β (-)-NC group). d HNF1β bound to the promoters of Derlin-1 in U87 and U251 glioma cells.
Transcription start site (TSS) was designated as +1. Putative HNF1β binding sites are indicated. Immunoprecipitated DNA was amplified by PCR.
Normal rabbit IgG was used as a negative control. e Western blot analysis for HNF1β regulated IDVs of Derlin-1; they are shown using GAPDH as
endogenous control. Data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. HNF1β (+)-NC group; #P < 0.05 vs. HNF1β
(−)-NC group
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miR-217 inhibited cell proliferation, migration, and inva-
sion, while induced apoptosis of SPC-A-1 and A549 cells
via targeting KRAS [40]. Our data demonstrated that
miR-217 expression was reduced in glioma tissues and
cells. Also, overexpression of miR-217 impeded glioma
cells malignancy in vitro and reduced tumor growth in
vivo. These findings indicated that miR-217 exerted
tumor-suppressive function in glioma cells.
HNF1β was first identified as a liver-specific transcrip-
tion factor and contributed to the malignant progression
of HCC. Recent studies showed that HNF1β functioned
as an oncogene in various tumors. HNF1β is upregulated
in human prostate cancer and favors cell proliferation
and tumor progression [41, 42]. Also, HNF1β expression
is increased in human pancreatic cancer and predicts
poor survival [21]. Due to the oncogenetic role of
HNF1β in various tumors, and the putative binding site
between miR-217 and HNF1β predicted with bioinfor-
matics databases, we hypothesized that HNF1β might be
involved in circ-TTBK2/miR-217 regulation network.
Luciferase assay result confirmed that HNF1β was a tar-
get of miR-217. Also, our data showed that HNF1β
served as an oncogene in glioma cells. We next aimed to
investigate whether HNF1β was involved in the circ-
TTBK2-mediated regulation of glioma cell progression.
As we expected, our results showed that circ-TTBK2 in-
hibition impaired HNF1β mRNA and protein expres-
sions. Moreover, reintroduction of miR-217 decreased
HNF1β mRNA and protein expressions by targeting its
3′-UTR. Additionally, overexpressed miR-217 reversed
circ-TTBK2-induced promotion of HNF1β expression.
These corroborated the hypothesis that HNF1β was in-
volved in circ-TTBK2/miR-217 regulation network.
In most cases, HNF1β serves as an activator in the
transcriptional regulation of targeted genes. Increasing
reports showed that Derlin-1 was upregulated in various
tumors. By analyzing the promoter sequence of Derlin-1,
two putative HNF1β binding sites were identified. ChIP
assays corroborate our hypothesis that HNF1β could dir-
ectly bind to Derlin-1 promoter. Furthermore, we dem-
onstrated that overexpressed HNF1β activated Derlin-1
expression. Similarly, HNF1β played key roles in the
regulation of intracellular cholesterol storage and the
level of free cholesterol via binding to and activating
ACAT promoter [28]. Overexpressed HNF1β favors
tumor progression and inhibits apoptosis of tumor cells
via enforcing osteopontin expression, which harbors
HNF1β binding sites in its promoter [43].
Notoriously, Derlin-1 acts as an oncogene in various
tumors. Earlier study showed that Derlin-1 was involved
in the TCL1-mediated contribution to progression of
chronic lymphocytic leukemia in mice [44]. In addition,
Derlin-1 is obviously upregulated in human lung cancer
cells, and the inhibition of Derlin-1 attenuates p62 degrad-
ation, which leads to the blockage of tumor cell autophagy
[45]. To describe the Derlin-1 profile in glioma tissues and
cells, the expression and function of Derlin-1 were deter-
mined. Consistent with previously reported, our results
demonstrated that Derlin-1 was located in the cytoplasm
and had a high expression in glioma tissues and cells. Fur-
ther, we found an enhanced expression of Derlin-1 that
stimulated glioma cell malignant behaviors. More import-
antly, overexpression of Derlin-1 had been proved to have
the ability to activate PI3K/AKT and ERK pathways in
tumor cells, which are the key pathways directly related to
proliferation, migration, invasion, and apoptosis [26, 27,
46, 47]. Given that Derlin-1 could be activated by HNF1β,
and miR-217 modulated glioma cell progression via
targeting 3′-UTR of HNF1β, we next sought to investigate
whether Derlin-1 and the downstream pathways were
involved in miR-217-induced blunting effect on glioma
cells. First, we found that overexpression of HNF1β
(without 3′-UTR) reversed inhibition on glioma cell ma-
lignant biological behavior induced by miR-217. Then, our
results demonstrated that Derlin-1, p-PI3K, p-AKT,
p-ERK, and p-MEK1/2 were distinctly restored when gli-
oma cells were co-transfected with miR-217 and HNF1β
(without 3′-UTR). These data provided a novel insight
into the molecular mechanism of circ-TTBK2 and
miR-217. The mechanism underlying tumorgenesis of
human glioma cell lines by circ-TTBK2 is schematically
presented in Fig. 8c.
(See figure on previous page.)
Fig. 6 Derlin-1 was upregulated in glioma tissues and cell lines and played oncogenic role in glioma cells. a Immunohistochemistry of Derlin-1 protein in
nontumorous brain, low-grade glioma, and high-grade glioma tissues. Original magnification: 100×. Scale bar = 50 μm. b Derlin-1 protein expression levels
in nontumorous brain tissues and glioma tissues using GAPDH as an endogenous control. Representative protein expression and their integrated density
values (IDVs) of Derlin-1 in nontumorous brain tissues, low-grade glioma tissues (World Health Organization (WHO) I–II), and high-grade glioma tissues
(WHO III-IV) are shown (data are presented as the mean + SD (n= 15, each group). **P < 0.01 vs. NBTs group; ##P < 0.01 vs. low-grade glioma tissues group).
Derlin-1 protein expression levels in astrocytes, U87, and U251 cells and using GAPDH as an endogenous control. Representative protein expression and
their IDVs in human normal astrocytes, U87, and U251 are shown (data are presented as the mean + SD (n= 15, each group). **P < 0.01 vs. human normal
astrocytes group). c CCK-8 assay was used to measure the proliferation effect of Derlin-1 on U87 and U251 cells. d Quantification number of migration and
invasion cells with reintroduction or knockdown of Derlin-1. Representative images and accompanying statistical plots were presented. Scale bars represent
40 μm. e Flow cytometry analysis of U87 and U251 cells with the expression of Derlin-1 changed. (Data are presented as the mean+ SD (n= 5, each
group). *P < 0.05 vs. Derlin-1 (+)-NC group; #P < 0.05 vs. Derlin-1 (−)-NC group)
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Fig. 7 miR-217 inhibited glioma cell malignant progression by regulating PI3K/AKT and ERK pathways via targeting HNF1β 3′-UTR. a CCK-8 assay was
applied to determine the proliferation effect of miR-217 and HNF1β on U87 and U251 cells (data are presented as the mean + SD (n = 5, each group).
Data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. miR-217+HNF1β group; #P < 0.05 vs. miR-217+HNF1β-NC group. b Quantification
of migration and invasion cells with the expression of miR-217 and HNF1β changed. Representative images and accompanying statistical plots were
presented (data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. miR-217+HNF1β group; #P < 0.05 vs. miR-217+HNF1β-NC group. Scale
bars represent 40 μm). c Flow cytometry analysis of U87 and U251 with the expression of miR-217 and HNF1β changed (data are presented as the
mean + SD (n = 5, each group). *P < 0.05 vs. miR-217+HNF1β group; #P < 0.05 vs. miR-217+HNF1β-NC group). d Western blot analysis of p-PI3K, PI3K,
p-AKT, AKT, p-ERK, ERK, p-MEK1/2, and MEK1/2 regulated by miR-217 and HNF1β in U87 and U251 cells, they are shown using GAPDH as endogenous
control (data are presented as the mean + SD (n = 5, each group). *P < 0.05 vs. miR-217+HNF1β group; #P < 0.05 vs. miR-217+HNF1β-NC group)
Fig. 8 In vivo study and the schematic cartoon of the mechanism of circ-TTBK2. a The stable expressing cells were used for the in vivo study. The nude mice
carrying tumors from respective groups were shown. The sample tumor from respective group was shown. b Tumor volume was calculated every 4 days
after injection, and the tumor was excised after 44 days. *P< 0.05 vs. control group; #P< 0.05 vs. miR-217 (+) group; ▲P< 0.05 vs. circ-TTBK2 (−) group. The
survival curves of nude mice injected into the right striatum (n= 15). P< 0.05 (miR-217 (+) or circ-TTBK2 (−) vs. control group); P< 0.01 (circ-TTBK2 (−)+miR-
217 (+) group vs. control group). c The schematic cartoon of the mechanism of circ-TTBK2 as an oncogene negative regulation of miR-217 in glioma cells
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Conclusions
In summary, our study revealed that circ-TTBK2 inhibition
restrained malignant progression of glioma cells by upregu-
lating miR-217. MiR-217 exerted tumor-suppressive func-
tion through downregulating HNF1β. HNF1β activated
Derlin-1 via binding to its promoter. More importantly,
inhibition of circ-TTBK2/miR-217/HNF1β/Derlin-1 axis
may be a potential therapeutic target for human gliomas.
Methods
Human tissues specimens
For determination of circ-TTBK2 and miR-217, clinical
specimens were divided into five group: NBTs (normal
brain tissues) (n = 11), grade I (n = 19), grade II (n = 19),
grade III (n = 19), and grade IV (n = 19). For determin-
ation of HNF1β and Derlin-1, clinical specimens were
divided into three groups: NBTs (n = 8), grade I–II gli-
oma group (low-grade glioma tissues) (n = 16), and grade
III–IV glioma group (high-grade glioma tissues) (n = 16)
based on the WHO 2007 classification of tumors by two
experienced neuropathologists. Normal brain tissues
(NBTs) were collected from patients’ fresh autopsy ma-
terial (donation from individuals who died in traffic acci-
dent and confirmed to be free of any prior pathologically
detectable conditions) were used as negative control.
Cell culture
Human U87 and U251 glioma cell lines and human em-
bryonic kidney (HEK) 293T cells were purchased from the
Shanghai Institutes for Biological Sciences Cell Resource
Center. Primary normal human astrocytes (NHA) were
purchased from the Sciencell Research Laboratories
(Carlsbad, CA, USA). For details, see Additional file 3.
Fluorescence in situ hybridization (FISH)
For identification of circ-TTBK2 and miR-217 rearrange-
ment in glioma tissues, circ-TTBK2 probe (green-labeled,
Biosense, Guangzhou, China) (5′ CAATCTTTCTCAATG
GTCTGACGTCA 3′) and miR-217 probe (red-labeled, Exi-
qon, Copenhagen, Denmark) were used. In brief, slides were
treated with PCR-grade proteinase-K (Roche Diagnostics,
Mannheim, Germany) blocked after with prehybridization
buffer (3% BSA in 4 × saline-sodium citrate, SSC). The
hybridization mix was prepared with circ-TTBK2 probe or
miR-217 probe in hybridization solution. Then the slides
was washed with washing buffer; the sections were stained
with anti-digoxin rhodamine conjugate (1:100, Exon Biotech
Inc, Guangzhou, China) at 37 °C for 1 h away from light.
The sections were stained with 4′,6-diamidino-2-phenylin-
dole (DAPI, Beyotime, China) for nuclear staining subse-
quently. All fluorescence images (100×) were captured using
a fluorescence microscope (Leica, Germany).
Reverse transcription and quantitative real-time PCR
Trizol reagent (Life Technologies Corporation, Carlsbad,
CA, USA) was used to extract total RNA from the clin-
ical tissues and NHA, U87, and U251 cells. See also
Additional file 3.
Western blot
Western blot was performed as previously described
[48]. See Additional file 3 for details and antibodies
used.
Cell transfections
Cell transfections were performed as previously described
[48]. See also Additional file 3.
Cell proliferation assay
Cell Counting Kit-8 assay (CCK-8, Dojin, Japan) was
used to investigate glioma cell proliferation. Also, see
Additional file 3.
Migration and invasion assays
Twenty-four-well chambers with 8-μm pore size (Corn-
ing, USA) was used for migration and invasion deter-
mination of U87 and U251 cells in vitro. For details, see
Additional file 3.
Apoptosis analysis
Cell apoptosis was determined by Annexin V-PE/7AAD
staining (Southern Biotech, Birmingham, AL, USA). See
also Additional file 3.
Reporter vectors construction and luciferase assays
Dual-luciferase assays were performed as previously
described [48]. See Additional file 3.
RNA immunoprecipitation
RNA immunoprecipitation was performed as previously
described [48]. In brief, glioma cells were lysed by a
complete RNA lysis buffer from an EZ-Magna RIP kit
(Millipore, Billerica, MA) according to the manufac-
turer’s protocol. See also Additional file 3.
Immunohistochemistry assays
The slides of human glioma tissue samples (4 μm thick)
were dewaxed, rehydrated, and incubated in 0.3% H2O2
for 10 min to inhibit endogenous peroxidase activity
before blocking with 10% normal goat serum (MXB,
Fuzhou, China) for 30 min and incubating overnight at
4 °C with rabbit polyclonal antibody against HNF1β
(1:150, SAB, Chicago, IL). Slides were washed with PBS
three times and then incubated with biotinylated rabbit
anti-rabbit IgG for 1 h at room temperature. After incu-
bation with avidinbiotin-peroxidase complex for 10 min,
samples were stained with 3, 3′-diaminobenzidine. Slides
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were imaged under a light microscope (Olympus, Japan)
at 100× magnification.
Chromatin immunoprecipitation assay
ChIP assay was conducted with Simple ChIP Enzymatic
Chromatin IP Kit (Cell signaling Technology, Danvers,
Massachusetts, USA) according to the manufacturer’s in-
struction as previously described [49]. In brief, glioma
cells were fixed with 1% formaldehyde and collected in
lysis buffer. Two percent aliquots of lysates were used as
an input control and the remaining lysates were immu-
noprecipitated with normal rabbit IgG or HNF1β anti-
body. Immunoprecipitated DNA was amplified by PCR
using their specific primers (as Additional file 4).
Tumor xenografts in nude mice
The tumor xenograft experiment was performed as pre-
viously described [48]. Stable expression U87 and U251
cells were used for in vivo study. For details, see also
Additional file 3.
Statistical analysis
Data are presented as mean + standard deviation (SD).
All statistical analyses were evaluated by SPSS 18.0 stat-
istical software with the Student’s t test or one-way ana-
lysis of variance ANOVA. Differences were considered
to be significant when P < 0.05. Corresponding signifi-
cance levels were indicated in the figures.
Additional files
Additional file 1: Figure S1. Circ-TTBK2 was resistant to RNase R
treatment, and the transfection efficiency of each target. a and b
Expression level of TTBK2 mRNA in glioma tissues and cells (data are
presented as the mean + SD (n = 5, each group)). c Expression level
of circ-TTBK2 in glioma cells with RNase R treatment (data are pre-
sented as the mean + SD (n = 5, each group), **P < 0.01 vs. control in
normal human astrocytes group; ##P < 0.01 vs. RNase R in Normal
human astrocytes group). d Expression level of TTBK2 in glioma cells
treated with RNase R (data are presented as the mean + SD (n = 5,
each group), **P < 0.01 vs. control group respectively). e qRT-PCR was
used to detect the transfection efficiency of circ-TTBK2 (data are
presented as the mean + SD (n = 5, each group). **P < 0.01 vs. circ-
TTBK2 (+)-NC group; ##P < 0.01 vs. circ-TTBK2 (−)-NC group). f qRT-
PCR was used to detect the transfection efficiency of sh-TTBK2 (data
are presented as the mean + SD (n = 5, each group). **P < 0.01 vs. sh-
NC group). g qRT-PCR was conducted to investigate the transfection
efficiency of miR-217 (data are presented as the mean + SD (n = 5,
each group). **P < 0.01 vs. pre-NC group; ##P < 0.01 vs. anti-NC
group). h Western blot was used to investigate the transfection
efficiency of HNF1β (data are presented as the mean + SD (n = 5,
each group). **P < 0.01 vs. HNF1β (+)-NC group; ##P < 0.01 vs. HNF1β (−)-NC
group). i Western blot was used to investigate the transfection efficiency of
Derlin-1 (data are presented as the mean + SD (n = 5, each group). **P < 0.01
vs. Derlin-1 (+)-NC group; ##P < 0.01 vs. Derlin-1 (−)-NC group). (TIF 781 kb)
Additional file 2: Figure S2. Correlation between miR-217 and TTBK2. a
qRT-PCR was conducted to detect expression levels of TTBK2 in glioma
cell treated with circ-TTBK2 (+) and circ-TTBK2 (−) (n = 5, each group). b
Expression level of circ-TTBK2 in cells treated with sh-TTBK2 (n = 5, each
group). c Expression level of TTBK2 in cells treated with pre-miR-217 and
anti-miR-217 (n = 5, each group). d The predicted two miR-217 binding
sites in TTBK2 (TTBK2-Wt and TTBK2-Wt1) and the designed mutant
sequences (TTBK2-Mut and TTBK2-Mut1) were indicated. e and f Luciferase
reporter assays of HEK 293T cells co-transfected with TTBK2-Wt (or TTBK2-
Wt1) or TTBK2-Mut (or TTBK2-Mut1), and miR-217 or the miR-217-NC (n = 5,
each group). (TIF 408 kb)
Additional file 3: Additional materials and methods. (DOCX 32 kb)
Additional file 4: Primers used for chromatin immunoprecipitation
assay. (XLSX 9 kb)
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